– USA, TN – Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced the appointments to its Board of Directors of Don Hardison as Chairman and Dr. Franklin Cockerill (MD) as Chief Medical Officer.
“Over the years, Don and Frank have provided invaluable support and strategic guidance as we launched and developed Decode Health. We’re honored they have accepted our invitation to expand their roles within the company. Their guidance and deep healthcare experience will strengthen our efforts to build a growing ecosystem of diagnostic, pharmaceutical, and technology partners to advance precision medicine and improve health outcomes,” said Co-Founder and CEO, Dr. Chase Spurlock.
About Don Hardison
Don Hardison was most recently President, CEO, and Board Member of Biotheranostics, Inc., a company developing molecular tests to guide cancer treatment. He previously was President, CEO, and Director of Good Start Genetics and EXACT Sciences Corp. For over 40 years, Hardison has held executive and senior management positions at companies including SmithKline Beecham, Quest Diagnostics, and LabCorp, where he served as COO. From 2016 to 2022, Hardison was a member of the Board of Directors of IQuity, Inc., a genomics company founded by the Decode Health leadership team to advance molecular diagnostics for autoimmune diseases. IQuity and Decode recently combined operations and now operate as Decode Health.
“I have worked with the team at Decode for many years and respect the passion they bring to their work,” said Don Hardison. “Decode is fueling an ecosystem of diagnostic, pharmaceutical, and technology partners that will accelerate biomarker and therapeutic discoveries. I am excited to continue my work with the Decode management team and other board members as we advance our mission to build a valuable company that delivers data, products, and services to advance precision medicine.”
About Dr. Franklin R. Cockerill, III
Dr. Cockerill is currently a founding partner of Trusted Health Advisors, a healthcare consulting and innovation group, and an adjunct professor of medicine at Rush University Medical Center. Before founding Trusted Health Advisors, Dr. Cockerill served as CEO, CMO, and Director of the Board of Analyte Health, a telehealth company, based in Chicago, IL. Prior to Analyte Health, Dr. Cockerill held several senior academic leadership roles, including service as Chair of the Department of Laboratory Medicine and Pathology at the Mayo Clinic in Rochester, MN, and President and CEO of Mayo Medical Laboratories (MML). Dr. Cockerill is board certified in internal medicine, infectious disease, and clinical microbiology.
“Decode is doing groundbreaking work in RNA genomics and advanced population health analytics that accelerates innovation and speed to value for diagnostic, pharmaceutical and technology companies building new products and services,” commented Dr. Cockerill. “I look forward to working with the Decode team, board members, and our partners as we work to advance precision medicine.”
About Decode Health
Decode Health is a healthcare AI company that powers an ecosystem of industry-leading diagnostic and pharmaceutical companies to unlock discoveries with data. Current projects include genomic data creation, RNA diagnostics, and population health analytics. Over the course of a decade, the team leading Decode has built a framework leveraging a variety of advanced machine learning approaches. The company’s flexible, scalable approach layers clinical data with SDoH and non-clinical data to fuel innovation and advance precision medicine. Decode’s data assets, products, and services improve patient outcomes, lower costs, and promote health equity.
For more information: https://www.decodehealth.ai/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.